Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer.

42 months: HR, 0.76; 95% CI, 0.63 to 0.91), with a nonsignificant trend toward improvement in those with tumor expression of PD-L1 ≥50% (median DFS not reached in either arm: HR, 0.82; 95% CI, 0.57 to 1.18).

also in 5,406 other papers